Search clinical trials for: ABT-614

Total 6246 results

Abbott

Completed

Exploratory Positron Emission Tomography (PET) Study to Evaluate the Effects of ABT-614 on [11C]-(+)-PHNO Binding Potential to D3 Receptors in the Brain

Healthy Volunteers

Canada
Abbott

Completed

A Study to Investigate the Process by Which ABT-614 is Absorbed, Distributed, Metabolized and Eliminated in Humans

Healthy

United States
Abbott

Completed

A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.

Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine

United States
Research Foundation for Mental Hygiene, Inc.

Completed

Attention-Bias Modification Treatment for PTSD

Posttraumatic Stress Disorder (PTSD)

United States
AbbVie

No longer available

Expanded Access to ABT-414

Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis
VA Office of Research and Development

Active, not recruiting

Non-Pharmacological Treatments for Insomnia in Chronic Traumatic Brain Injury

Insomnia | Traumatic Brain Injury

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study of ABT-414 in Subjects With Solid Tumors

Squamous Cell Tumors

United States, Canada
Gonzalez-Heydrich, Joseph, M.D.

Unknown

Anger Control Therapy (ACT) With RAGE-Control: An Outpatient Videogame-assisted Therapy for the Treatment of Anger

Anger | Aggression

United States
Erasmus Medical Center

Terminated

Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders (ATTENTIO)

Generalized Anxiety Disorder | Social Anxiety Disorder | Specific Phobia | Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood, Early Onset

Netherlands
AbbVie
Radiation Therapy Oncology Group

Completed

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)

Glioblastoma | Gliosarcoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Germany, Hong Kong, Ireland, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Portugal, Russian Federation, Singapor... and more
IRCCS Eugenio Medea

Recruiting

Pragmatic Abilities in Children With Acquired Brain Injury (ABIabc)

Acquired Brain Injury | Pragmatic Communication Disorder

Italy
Amgen

Completed

Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

Advanced Renal Cell Carcinoma
Amgen

Completed

Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer

Metastatic Colorectal Cancer
Fred Hutchinson Cancer Center
University of Washington

Completed

Innovative Smartphone Application of a New Behavioral Method to Quit Smoking: Pilot Trial (Smart Quit)

Smoking

United States
Abbott

Completed

Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation

Irritable Bowel Syndrome

Pakistan
National Taiwan University Hospital

Recruiting

Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection

H. Pylori Infection

Taiwan
Chang Gung Memorial Hospital

Completed

Comparison of Choosing Free ALT or Free PMT for Reconstruction With Head and Neck Cancer

Head and Neck Cancer | Reconstructive Surgery

Taiwan
University of Cyprus
University of Crete

Unknown

Acceptance and Commitment Therapy and Cognitive Behavioral Therapy for Chronic Pain (ALGEA)

Chronic Pain

Greece
Abbott

Completed

Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers

HCV Infection

United States
AbbVie

Recruiting

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Serbia, Spain, Taiwan, Turkey, United... and more
Miguel Monfort Montolio

Not yet recruiting

Efficacy of Animal-assisted Therapy in Patients With Borderline Personality Disorder and Addictions.

Diagnosis, Dual (Psychiatry)
Fred Hutchinson Cancer Center
Consumer Wellness Solutions

Completed

Improving Smoking Cessation Quitlines: Pilot Study of Acceptance Therapy (TALK)

Smoking

United States
AbbVie

Completed

Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function

Renal Impairment

United States, New Zealand
AbbVie

Completed

The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4) (ENDURANCE-4)

Hepatitis C Virus
Miguel Monfort Montolio

Completed

Animal-Assisted Therapy in the Residential Treatment of Schizophrenia and Addictions

Diagnosis, Dual (Psychiatry)
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection (ENDURANCE-2)

Chronic Hepatitis C Virus (HCV) Infection
Tel Aviv University

Completed

Home-Delivered Attention Control Treatment for Post Traumatic Stress Disorder (PTSD)

PTSD

Israel
Sorlandet Hospital HF
University of Oslo; Karolinska Institutet; University of Oxford; The Hospital of... and other collaborators

Completed

Secondary Prevention of Depression Through Group-based ACT-Therapy Preceded by an Experimental ABM-Procedure

Major Depression

Norway
Veterans Medical Research Foundation
National Institute of Mental Health (NIMH)

Completed

Assertive Community Treatment With CBT and SST for Schizophrenia

Schizophrenia

United States
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) (EXPEDITION-2)

Hepatitis C Virus Infection | Chronic Hepatitis C | Human Immunodeficiency Virus Infection | Compensated Cirrhosis and Non-cirrhotics
Tel Aviv University

Completed

ACT With Feedback for Post Traumatic Stress Disorder (PTSD)

PTSD

Israel
AbbVie

Completed

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

United States, New Zealand
Joseph Brant Hospital

Unknown

Triple Aim Psychotherapy: Aimed at Improving Patient Experience, Population Health, and Cost (TAP)

Depressive Symptoms | Anxiety Symptoms

Canada
The University of Hong Kong
The Hong Kong Jockey Club Charities Trust; Hong Kong Young Women's Christian... and other collaborators

Recruiting

Acceptance and Commitment Therapy and Exercise for Older Adults With Chronic Pain

Chronic Pain | Exercise | Older Adults | Acceptance and Commitment Therapy | Psychosocial Intervention | Art

Hong Kong
AbbVie

Completed

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis (EXPEDITION-8)

Hepatitis C Virus (HCV)

United States, Bulgaria, Canada, Czechia, France, Greece, Hungary, Ireland, Israel, Italy, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Spain, Taiwan, United Kingdom, Vietnam
AbbVie

Approved for marketing

Expanded Access to Glecaprevir/ Pibrentasvir

Hepatitis C Virus Infection

Slovenia
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-4)

Chronic Hepatitis C Virus (HCV) Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

Chronic Hepatitis C Infection
University of Wisconsin, Madison
National Institute of Mental Health (NIMH)

Not yet recruiting

Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons

Depression | Anxiety Disorders | Anxiety | Depression, Anxiety
University of Alcala
Hospital Universitario Principe de Asturias

Completed

Predictors and Moderators of Cognitive-Behavioral Therapy and Acceptance and Commitment Therapy for Panic Disorder

Panic Disorder | Acceptance and Commitment Therapy | Predictor | Cognitive-Behavioral Therapy

Spain
AbbVie

Completed

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Chronic Hepatitis C | Hepatitis C Virus | Compensated Cirrhosis
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection

Hepatitis C Virus (HCV)

Brazil
The Miriam Hospital

Unknown

Project CORE: Disseminating Eating Disorders Treatment

Eating Disorders in Adolescence | Anorexia Nervosa/Bulimia | Anorexia Nervosa Restricting Type

United States
AbbVie

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy

Chronic Hepatitis C | Hepatitis C Virus | HCV | Direct-Acting Antiviral Agent (DAA)-Experienced
Abbott

Completed

Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia

Schizophrenia

United States
AbbVie

Active, not recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Hepatitis C Virus (HCV)

United States, Australia, Austria, Canada, France, Germany, Italy, Spain
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Cognitive Deficits in Schizophrenia

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection

Chronic Hepatitis C Infection
AbbVie

Completed

A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis

Erosive Hand Osteoarthritis
Abbott

Completed

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects

Healthy

United States

3

Subscribe